The European Agency for the Evaluation of Medicinal Products
Evaluation of Medicines for Human Use

London, 4 December 2000
Doc. Ref: EMEA/H/2681/00/Final

WITHDRAWAL OF THE MARKETING AUTHORISATION FOR THE MEDICINAL PRODUCT "PRIMAVAX - Diphtheria, Tetanus and Hepatitis B vaccine" EU/1/97/056/001

- On 5 February 1998, the European Commission issued a Marketing Authorisation valid throughout the European Union for the medicinal product Primavax, which is a combined trivalent vaccine. The pharmaceutical company responsible for this medicinal product is Aventis Pasteur MSD S.N.C.
- On 18 May 2000, the Marketing Authorisation holder notified the European Commission about the Marketing Authorisation holder's decision to withdraw the Marketing Authorisation for Primavax.
- On 27 July 2000, the European Commission adopted the decision, withdrawing the Marketing Authorisation for the medicinal product for human use "PRIMAVAX - Diphtheria, Tetanus and Hepatitis B vaccine" EU/1/97/056/001. Pursuant to this decision the European Public Assessment Report for Primavax has been removed from the EMEA website.

Mr. Noel Wathion
Head of Unit
Evaluation of Medicines for Human Use
Tel.: (+44-20-7) 418 8592
Fax: (+44-20-7) 418 8668

7 Westferry Circus, Canary Wharf, London, E14 4HB, UK
Switchboard (44-20-7) 418 8400 Fax (44-20-7) 418 8613
E-mail: mail@emea.eudra.org http://www.eudra.org/emea.html
EMEA 2000 Reproduction and/or distribution of this document is authorised for non-commercial purposes only provided the EMEA is acknowledged